'Intractable', 'refractory' and 'resistant' are synonyms which may be used to describe hypertensive patients in whom blood pressure control is unsatisfactory despite the concurrent administration of three or more conventional hypotensive agents (beta-blocker plus diuretic plus either prazosin, hydralazine or methyldopa) in the maximum tolerated dose. The level of arterial pressure which is deemed to be unsatisfactory varies from clinician to clinician: a diastolic pressure of 110mmHg or greater despite treatment is one arbitrary level (Mackay et al. 1981 a) but, since blood pressure normally varies with sex and rises with age (Hamilton et al. 1954) , a more accurate though equally arbitrary definition could be blood pressure despite treatment of greater than one standard deviation above the age-and sex-related mean value for a normal outpatient population (Mackay et al. 1983) . Patients with intractable hypertension are commonly referred to a specialist hypertension clinic, and their management may usefully be approached by considering the following reasons for poor control.
Compliance: Poor compliance is the commonest cause of poor blood pressure control: up to a ha~f of all asymptomatic patients started on anuhypertensive medication fail to comply within three months (Wilber & Barrow 1972 , Sackett 1977 , and the temptation not to persevere with treatment is all the greater where complicated drug regimens with multiple side effects are prescribed. Forgetfulness, social isolation and psychiatric illness also playa part, particularly in older patients, but even young intelligent patients who are fully informed about their condition may fail to take medication regularly. No easy solution exists but calendar packs, once-or twicedaily medication (few hypotensive agents require to be administered three or more times daily) and good rapport with, and careful follow up by, one clinician may help to minimize the pr?blem.
Detecting non-compliance may be difficult, however: one helpful marker is the resting pulse rate, which should be slow if the patient is taking a. beta-blocker such as propranolol or~ten?lo.l, Since these drugs do not have intnnsic sympathomimetic activity. 0141-Q768/83/070537-n3/$01.00/0
Adequate dosage: If patients are free from the side effects of conventional hypotensive agents in modest dosage, then maximal dosages should be administered before pronouncing that the hypertension is resistant. Where side effects are troublesome, changing the responsible agent to an allied drug with similar hypotensive action but different pharmacological properties may be successful; for example, altering the beta-blocking agent such as propranolol to a cardioselective drug with low lipid solubility such as atenolol. Further useful therapeutic manoeuvres include changing to a drug with multiple hypotensive actions instead of one with a single action: labetalol, which combines alpha-with betablockade, can replace a beta-blocker; or indaparnide, which combines mild diuretic activity with other hypotensive and possibly vasodilator action, can replace a thiazide diuretic (Campbell & Moore 1981) . On the other hand, the assumption that because a thiazide diuretic is ineffective in controlling blood pressure when administered alone, it will also be ineffective when administered in combinations with one or two other agents, is clearly fallacious.
False tolerance: All common hypotensive agents except dIUretICS and beta-blockers may induce sodium and water retention with expansion of plasma and extracellular fluid volume and loss of blood pressure control -the phenomenon termed 'false tolerance' (Gifford 1974 , Ramsay et al. 1980 ). An increase in the dose and/or potency of the diuretic in the drug combination may be all that is required to restore normal blood pressure. In this context, the combination of a thiazide and spironolactone may' be useful (Kincaid-Smith et al. 1973) . Furthermore, in patients with normal renal function, loop diuretics (frusemide bumetanide, ethacrynic acid) may provẽ ffective where thiazides have failed. Where renal impairment with a creatinine clearance less than 20 ml/minute exists, thiazides are unlikely to be effective whereas loop diuretics retain their potency (Mroczek et al. 1974 ).
Undetected secondary hypertension:
A cause of secondary hypertension may have been undetected at the outset of treatment or may have developed during treatment. This possibility should be examined, particularly where previously well-controlled blood pressure has undergone progressive deterioration in a compliant patient (Mackay et al. 198Ia) . Possible diagnoses include drug-induced hypertension (e.g. oral contraceptives, steroids, liquorice), renal artery stenosis, coarctation of the aorta, adrenocortical adenoma, phaeochromocytoma, and the 'pseudo-phaeochromocytorna' syndrome which may occur with posterior fossa tumours (Mackay et al. 1978) . Useful investigations include plasma urea and electrolyte concentrations, plasma renin angiotensin II and aldosterone concentrations, urinary normetadrenaline estimations, chest Xray, intravenous urography, isotope renography and, where relevant, computerized tomography brain scan.
For the minority of patients in whom this fourpart assessment has failed to remedy unsatisfactory blood pressure control, two recently introduced oral agents will control blood pressure almost without exception (Mackay et al. 1981 a) . Indeed, even where blood pressure control is already satisfactory but the side effects of conventional drugs are troublesome, substitution of one of these agents will be effective. These drugs are minoxidil, a powerful arteriolar vasodilator; and captopril, the only oral converting enzyme inhibitor currently available on general prescription.
The antihypertensive potency and long-term effectiveness of minoxidil has been established in patients with intractable hypertension secondary to all causes and with all levels of renal impairment (Mackay et al. 1981b) . However, prescription of minoxidil must be combined with that of a beta-blocker and a diuretic (usually a loop diuretic) to combat the tachycardia and fluid retention which accompany its use. Minoxidil is rapidly absorbed and bound to arteriolar walls, so that in patients requiring haemodialysis the procedure may be commenced safely two hours after administration of the drug. Metabolism of minoxidil is principally by conjugation with glucuronic acid in the liver, and so the dosage need not be moderated in renal failure. A oncedaily dosage of 2.5-40 mg is satisfactory in 80% of patients, although if a very large fall in blood pressure is necessary then a twice-daily dosage is desirable to dampen diurnal swings in pressure. Minoxidil should be added to a betablocker/diuretic combination in an initial dose of 2.5 or 5 mg and the dosage increased by 2.5 or 5 mg at two-or three-day intervals until control is achieved.
The development of haemorrhagic right atrial lesions in dogs given minoxidil was a finding which hampered early work, but this effect has since been shown to be species-specific (Sobota et al. 1980) . Nonspecific T-wave electrocardiogram changes, on the other hand, are a common but transient phenomenon in man, but no harmful haemodynamic or clinical effects have been recorded (Hall et al. 1979) . The principal side effect of minoxidil is fluid retention; this is more marked at higher dosages but is easily reversed following an increase in the dosage of diuretic, except in patients with severe chronic renal failure in whom the diuretic may be less effective and the need for dialysis may thereby be hastened. Symptomless pericardial effusion may also Occur and, rarely, may be life-threatening, but is again most troublesome in patients with end-stage renal failure. Because fluid retention is a potential problem, patients taking minoxidil must regularly weigh themselves and report any rapid weight gain of 3 kg (71b) or more to their physician. Frequent routine outpatient review is necessary in the early months of treatment, but twice-yearly review may be acceptable thereafter. Hirsutism is a further side effect of minoxidil applauded by most male patients, but sufficiently distressing to women to preclude its use. A small number of males treated with minoxidil develop gynaecomastia.
Captopril is an oral inhibitor of converting enzyme the peptidyldipeptide hydrolase responsible for conversion of angiotensin I to angiotensin II and involved in the degradation of bradykinin. In combination with a diuretic, captopril is also strikingly effective in the treatment of resistant hypertension (Atkinson et al. 1980b , White et al. 1980 . The principal mode of action appears to be through reduction in circulating angiotensin II and aldosterone levels, although delayed degradation of bradykinin, increased prostaglandin release (Swartz et al., 1980) , decreased sympathetic transmission and diminished baroceptor function also may be involved (Clough et al. 1980) . Natriuresis following administration of a diuretic to any individual prompts a compensatory increase in renin sec)etion, with consequent increases in plasma angiotensin II and aldosterone levels and restoration of normal sodium balance: an explanation for the success of the diuretic/captopril combination may be that this homeostatic mechanism is interrupted, allowing free diuretic activity (Atkinson et al. 1980a) . It is usually necessary to administer maintenance dosages of captopril ranging from 25 to 150 mg twice or thrice daily in patients with normal renal function; but since it is mainly excreted undegraded by the kidneys, it is advisable to reduce the dosage in patients with chronic renal failure -one dose every two to three days may be all that is required where creatinine clearance is 8-19 ml/minute (Heel et al. 1980) . Rarely, where the patient's elevated blood pressure is dependent on markedly-elevated angiotensin II levels, a precipitate and potentially hazardous fall in blood pressure may follow administration of the first dose of captopril. In a hypertensive patient who is salt-depleted, the danger of this reaction is much greater. To protect against this effect the first dose should therefore be small (I mg, 3 mg or 6.25 mg) and preferably administered under inpatient observation. The hypotension may be reversed by infusion of angiotensin II or hypertonic saline (Atkinson et al.1980a) .
Early estimates of the incidence of many of the side effects of captopril may have been exaggerated by excessive dosage of the drug in patients with renal impairment, but transient loss of taste, maculopapular skin rash, membranous glomerulopathy and rarely agranulocytosis may still occur (Lancet 1980) . Reduction in the dose or withdrawal of captopril may lead to full recovery from the glomerulopathy, though this does not necessarily take place; on the other hand, the glomerulopathy may resolve despite continuation of captopril in its previous dosage. It is striking how many of these side effects also occur after penicillamine, a drug which also contains a sulphydryl group. Current evaluation of a second generation of oral converting enzyme inhibitors without a sulphydryl group is therefore of particular interest. Among further effects of captopril, and in parallel with the fall in plasma aldosterone levels, is a rise in plasma potassium concentration of I mmol/l on average, so that concomitant potassium supplementation may be hazardous. Tachycardia occasionally occurs after captopril but responds to beta-blockade.
One further hazard of reducing to 'normal' the blood pressure of patients with longstanding resistant hypertension is a failure to perfuse adequately tissues or organs distal to a fixed arterial stenosis. This may manifest itself as intermittent claudication or unremitting ischaemia of a limb, deteriorating renal function, angina pectoris or cerebral confusion.
Though side effects are rightly emphasized with new agents such as minoxidil and captopril, serious side effects are rare and the majority of patients who are changed to either of these drugs remark on a feeling of considerable wellbeing: this may be attributed in large measure to relief from undesirable effects of conventional drugs, particularly drowsiness, dizziness and impotence.
There is no published evidence comparing the efficacy of minoxidil and captopril in appropriate drug combinations under controlled conditions. However, in terms of side effects it seems prudent to avoid cosmetic problems with minoxidil in women, while for men both regimens are acceptable. Certainly, both combinations of drugs offer the means substantially to improve the morbidity and mortality of patients who are poorly controlled on conventional antihypertensive drugs, and who therefore remain at high risk of developing stroke, myocardial infarction, cardiac failure and renal failure.
